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Nodal, a secreted signaling protein from the transforming growth factor beta (TGF-β)-super
family plays a vital role during early embryonic development. Recently, it was found that
maternal decidua-speciﬁc Nodal knockout mice show intrauterine growth restriction (IUGR)
and preterm birth. The chromosomal location of NODAL is in the same linkage area as
the placental (fetal) pre-eclampsia (PE) susceptibility gene STOX1, which is associated
with the familial form of early-onset, IUGR-complicated PE. As the STOX1 linkage was
originally identiﬁed in women being born from a pre-eclamptic pregnancy as well as
suffering from PE themselves, the linkage could in part be caused by NODAL, which is
why the potential maternal–fetal interaction between STOX1 andNODALwas investigated.
In the PE families with the STOX1 susceptibility allele carried by the children born from
pre-eclamptic pregnancies, it was found that the pre-eclamptic mothers themselves all
carried the NODAL H165R SNP, which causes a 50% reduced activity. Surprisingly, in
decidua-speciﬁc Nodal knockout mice the fetal placenta showed up-regulation of STOX1
and NODAL expression. Conditioned media of human ﬁrst trimester decidua and a human
endometrial stromal cell line (T-HESC) treated with siRNAs against NODAL or carrying
the H165R SNP were also able to induce NODAL and STOX1 expression when added to
SGHPL-5 ﬁrst trimester extravillous trophoblast cells. Finally, a humanTGF-β/BMP signaling
pathway PCR-array on decidua and the T-HESC cell line with Nodal knockdown revealed
upregulation of Activin-A, which was conﬁrmed in conditioned media by ELISA. We show
that maternal decidua Nodal knockdown gives upregulation of NODAL and STOX1 mRNA
expression in fetal extravillous trophoblast cells, potentially via upregulation of Activin-A
in the maternal decidua. As both Activin-A and Nodal have been implicated in PE, being
increased in serum of pre-eclamptic women and upregulated in pre-eclamptic placentas
respectively, this interaction at the maternal–fetal interface might play a substantial role in
the development of PE.
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INTRODUCTION
Pre-eclampsia (PE) is a humanpregnancy-associateddisease, char-
acterized by maternal hypertension and proteinuria, that occurs
in about 2–8% of pregnancies. It remains the leading cause of
maternal and fetal morbidity and mortality with an increase in
incidence each year (WHO, 2011). The symptoms of PE do not
present until 20 weeks of gestation onward; however, the origin
can be found in the ﬁrst trimester. During normal early pregnancy,
trophoblast cells invade the placental bed, modifying the spiral
arteries from low-ﬂow high-resistance to high-ﬂow low-resistance
vessels in order to reach the demands of the developing fetus. In
PE patients, aberrant trophoblast differentiation, limited migra-
tion and invasion of the trophoblasts into the uterus, and poor
remodeling of spiral arteries, as well as excessive apoptosis are all
seen during placentation (Steegers et al., 2010).
During pregnancy, a complex interface is formed between
the maternal decidua and fetal placenta, and both are involved
in the secretion of and responses to essential regulatory factors
that modify the maternal–fetal interface surroundings to create
the conditions and anatomical structures necessary to protect the
mother and the fetus (Audus et al., 2002). This process is partially
driven by hormones, but it has become increasingly evident that
a large number of factors like cytokines, growth factors (Lunghi
et al., 2007; Knoﬂer, 2010), and also members of the transform-
ing growth factor beta (TGF-β) superfamily (Jones et al., 2006) are
essential. The TGF-β superfamily is a large family of proteins that
consists of growth and differentiation factors that are responsible
for cell differentiation, proliferation, and embryo development.
This family includes TGF-β, Activins, Inhibins, and Nodal, which
are all excreted and subsequently are able to function in a paracrine
or autocrine manner.
Recently, it was found that offspring of maternal decidua-
speciﬁc Nodal knockout mice showed intrauterine growth restric-
tion (IUGR) and spontaneous preterm birth (Park et al., 2012),
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due to disruption of the normal parturition cascade. The chro-
mosomal location of NODAL is in the same linkage area as the
placental (fetal) PE susceptibility gene STOX1, which is associ-
ated with the familial form of early-onset, IUGR-complicated PE
(van Dijk et al., 2005). The PE susceptibility linkage locus origi-
nally identiﬁed on chromosome 10q22 by microsatellite marker
analysis showed matrilineal inheritance (Oudejans et al., 2004).
Investigating the individual genes on this locus for imprinting fea-
tures revealedNODAL as one of the genes with reduced expression
in the androgenetic placenta, suggestive of imprinting. As the PE
linkage was originally identiﬁed in women who were both born
from a complicated pregnancy (PE, pregnancy induced hyperten-
sion) and suffering from PE during their own pregnancies, the
microsatellite marker linkage could in part be caused by NODAL,
which is why this study investigated the potential maternal–fetal
interaction between STOX1 and NODAL.
RESULTS
NODAL H165R SNP IN DUTCH PRE-ECLAMPTIC MOTHERS
Previously, we identiﬁed matrilineal transmission of the STOX1
Y153HSNP inDutch pre-eclamptic families (vanDijk et al., 2005).
STOX1 functions in the fetal placenta as it affects trophoblast inva-
sion (van Dijk et al., 2010b). Indeed, the STOX1 Y153H SNP was
identiﬁed to occur in children born out of pre-eclamptic pregnan-
cies in all families investigated. Sequencing of theNodal gene in the
same PE families used to identify the STOX1 Y153H SNP revealed
that all pre-eclamptic mothers, who gave birth to a child carrying
the STOX1 Y153H SNP, themselves carried the NODAL H165R
SNP (rs1904589; Figure 1). This indicates that theNODAL H165R
SNP might affect the pre-eclamptic phenotype at the maternal
level. NODAL potentially also shows a parent-of-origin effect.
Further evidence was provided by the pedigrees where the allele
containing theNODALH165RSNP inwomenwho suffered froma
FIGURE 1 | Pedigree structure of three generations of Dutch
pre-eclampsia families with linkage to chromosome 10q22.
Females in generation I had either pregnancy-induced hypertension
(gray circle) or pre-eclampsia (dark circle). All sisters in generation II had
pre-eclampsia and were born from pregnancies complicated by
pre-eclampsia or pregnancy-induced hypertension. Generation III
depicts the children born from pre-eclamptic pregnancies.Where the
parental origin of the allele could be determined the maternal allele is
depicted by capital letters. The STOX1 and NODAL SNPs contributing
to the pre-eclampsia phenotype, at placental and maternal level
respectively, are indicated in red. As the pre-eclampsia linkage in this locus
showed matrilineal transmission, only the STOX1Y153H SNP with maternal
origin is marked in red. Individuals born from complicated pregnancies
(generation II and III) all carry the STOX1Y153H SNP. Mothers who suffered
from a complicated pregnancy (generation I and II) all carried the NODAL
H165R SNP originating from the mother (marked in red), except in families
PE_9046 and PE_9526 where the SNP in generation II originates from the
father.
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complicated pregnancy originated from their mother in ﬁve out of
seven families. This SNP, although very common with a heterozy-
gosity of around 50% in Caucasians of European ancestry, has
been described to have less than 50% bioactivity (Roessler et al.,
2009). In the case of a parent-of-origin effect maternal transmis-
sion of this allele would lead to a 50% reduction in activity, while
normal transmission would result in about 25% less activity in
heterozygotes.
UTERINE NODAL KNOCKOUT MICE SHOW UPREGULATION OF NODAL
IN THE FETAL PLACENTA
To gain insight into the potential interaction between NODAL and
STOX1 we examined the expression of Nodal and Stox1 mRNA in
the fetal part of the placenta of a transgenic mouse strain with
maternal-speciﬁc deletion of Nodal in decidua. In short, tissue-
speciﬁc conditional knockout was accomplished by utilizing a
loxP ﬂanked Nodal strain and progesterone receptor (Pgr)-Cre
mice eliminating Nodal from the maternal reproductive tract at
the onset of sexual maturity without altering the fetal layers of
the placenta at the genomic level (Park et al., 2012). Interest-
ingly, these uterine Nodal knockout mice (Nodal/) showed
signiﬁcant upregulation of Nodal and Stox1 mRNA expression
(Figure 2) in the fetal placenta (d16.5) compared to control
mice (Nodal+/+). Maternal uterine tissues showed downregu-
lated expression of Nodal upon knockout as expected (data not
shown).
HUMAN DECIDUA SHOWS SIMILAR EFFECTS AS SEEN IN MICE
We tested if the effects of decidual Nodal knockdown on placen-
tal expression as found in mice could also be seen in the human
placenta. For this, we collected ﬁrst trimester decidual tissues car-
rying either wildtype or NODAL H165R SNP alleles. Conditioned
media from these gestational age-matched decidual tissues (week
6 and week 8–9) were added to SGHPL-5 cells, a ﬁrst trimester
extravillous trophoblast cell line. These cells subsequently showed
upregulation of both NODAL and STOX1 expression when the
conditioned media was from decidual tissue carrying the H165R
FIGURE 2 | Nodal and Stox1 mRNA expression in mouse placental
tissue (d16.5). Nodal and Stox1 mRNA expression in the fetal part of the
placenta of uterine Nodal knockout (Nodal/; n = 3) relative to control
(Nodal+/+; n = 3) mice. *P < 0.05.
SNP alleles (Figures 3A,B). In this small number of decidua tis-
sues (n = 2 in each group), statistical signiﬁcance was reached
for STOX1 expression showing upregulation at a gestational age
of 6 weeks, while the observed upregulated STOX1 expression at
gestational age 8–9 weeks and upregulated NODAL expression
at both gestational age timepoints did not reach statistical sig-
niﬁcance. SGHPL-5 cells incubated with conditioned media of
decidual tissues (week 8–9) treated with siRNAs against Nodal or
scrambled controls showed signiﬁcant upregulation of NODAL,
while the upregulated STOX1 expression observed did not reach
statistical signiﬁcance (Figure 3C).
LOCALIZATION OF NODAL IN HUMAN DECIDUA
Nodal in mice was reported to be expressed in glandular epithelial
cells prior to implantation, while after implantation Nodal was
detectable in the outer stromal region before eventually becoming
restricted to the decidua parietalis of the mature maternal decidua
(Park and Dufort, 2011). Although Nodal expression has been
reported to be expressed in the human placenta throughout preg-
nancy (Roberts et al., 2003), Nodal has not yet been investigated in
human ﬁrst trimester decidua. By immunohistochemistry of ﬁrst
trimester decidua tissues human Nodal was found to be localized
in glandular epithelial cells (Figure 4A), placental derived extrav-
illous trophoblast cells, and in decidual stromal cells (Figure 4B),
similar to that detected in mice.
UNDIFFERENTIATED DECIDUAL STROMAL CELLS CAUSE THE EFFECTS
SEEN IN PLACENTA
As Nodal was found to be expressed in both glandular epithe-
lial cells and decidual stromal cells, human decidual cell lines
were used to see which of the two cell types were at the origin
of the effects observed. Ishikawa cells, a cell line representative of
glandular epithelial cells were tested by using Nodal siRNA knock-
down after which the conditioned media was added to SGHPL-5
cells after which NODAL and STOX1 mRNA expression levels
were measured. The conditioned media of Ishikawa cells did not
yield similar effects to the effects seen when conditioned media of
decidual tissues were used (data not shown). A human endome-
trial stromal cell line, T-HESC, which can be differentiated to
form decidualized cells, was used undifferentiated as a model for
endometrial stromal cells and differentiated as a model for decid-
ualized cells. In undifferentiated T-HESC cells, siRNA treatment
against Nodal led to a signiﬁcant upregulation of NODAL mRNA
in SGHPL-5 cells after the addition of T-HESC conditionedmedia,
while STOX1 expression levels were highly variable (Figure 5A).
Addition of conditioned media from differentiated T-HESC cells
treated with Nodal siRNAs to SGHPL-5 cells were able to upregu-
late NODAL, while STOX1 mRNA expression was downregulated
(Figure 5B).
ACTIVIN-A AS SIGNALING FACTOR BETWEEN DECIDUA AND PLACENTA
We used a human TGF-β/BMP signaling pathway PCR array to
investigate potential molecules responsible for upregulation of
NODAL and STOX1 as seen upon treatment with conditioned
media of decidual tissues and cells with reduced Nodal activity
or expression. Using this array we studied the mRNA expression
proﬁle of undifferentiated T-HESC cells as well as week 8 decidua
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FIGURE 3 | NODAL and STOX1 expression in SGHPL-5 cells after addition
of decidual tissue conditioned media. NODAL (A) and STOX1 (B) mRNA
expression in SGHPL-5 cells treated with decidua conditioned media from
gestational age-matched week 6 (n = 4) and week 8–9 (n = 4) decidua tissues
carrying Nodal H165R (n = 2 per gestational age) relative to wildtype (WT;
n = 2 per gestational age) alleles. (C) NODAL and STOX1 mRNA expression
in SGHPL-5 cells treated with decidua conditioned media from deciduas
treated with Nodal siRNAs relative to scrambled control (n = 4). *P < 0.05.
tissue after transfection with siRNAs against Nodal and scrambled
controls.
One-third (26 genes) of the genes present on the array showed
differential expression between scrambled and Nodal siRNAs in
both cells and tissue. Our interest was focused toward ligands
as they are excreted and therefore could potentially function as
signaling molecule between decidua and placenta. Nodal expres-
sion as seen in SGHPL-5 cells is initiated by ligands binding to
membrane-bound Activin receptors, therefore our choice of can-
didate ligandswas based on their ability to either activate or inhibit
Activin receptors. The differentially expressed mRNAs that ful-
ﬁlled these requirements were INHBA, INHBB, GFD3, and FST,
which were all upregulated in the Nodal siRNA treated samples
compared to scrambled controls. INHBA codes for Activin-A, and
asActivin-A has been implicated in PE being increased inmaternal
serum of pre-eclamptic patients (Giguere et al., 2010), we decided
to verify the excretion of this ligand. We performed veriﬁcation
of excretion by ELISA on the conditioned media of decidua tis-
sues and T-HESC cell lines transfected with siRNAs. Following
siRNA treatment, there was no measurable difference in the level
of Activin-A in the conditioned media from Nodal siRNA-treated
cells or decidua compared to those treated with scrambled siR-
NAs. Therefore, T-HESC cells transfected with wildtype or H165R
Nodal constructs were used which lead to an overexpression of
Nodal with full bioactivity (wildtype) or 50% reduced bioactivity
(H165R). Conditioned media of H165R-Nodal in undifferenti-
ated T-HESC cells showed signiﬁcantly higher expression levels of
Activin-A compared to wildtype (Figure 6A). Furthermore, com-
pared to transfections with empty vector, conditioned media of
wildtypeNodal transfected cells reduced the expression of Activin-
A signiﬁcantly. Differentiated T-HESC cells did not show any
difference in expression level between empty vector, wildtype and
H165R (Figure 6B).
DISCUSSION
Work performed in this study shows that maternal Nodal is able
to regulate fetal placental NODAL and, potentially, STOX1 expres-
sion through Activin-A excretion at the maternal–fetal interface.
Firstly, we identiﬁed that pre-eclamptic mothers whose children
carry the STOX1Y153H SNP themselves carry the NODAL H165R
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FIGURE 4 | Localization of Nodal in human first trimester decidua.
(A) Immunohistochemistry showing expression of Nodal (green) in epithelial
glandular cells. (B) Localization of Nodal (green) in placental derived
extravillous trophoblast cells [positive for both Nodal (green) and cytokeratin 7
(red), arrowheads] and decidual stromal cells [positive for Nodal (green),
negative for cytokeratin 7 (red), arrows].
FIGURE 5 | Expression in SGHPL-5 cells after addition of conditioned
media ofT-HESC cells. (A) NODAL and STOX1 mRNA expression
in SGHPL-5 cells after addition of conditioned media from
undifferentiatedT-HESC cells treated with siRNAs against Nodal relative to
scrambled control (n = 5). (B) NODAL and STOX1 mRNA expression in
SGHPL-5 cells after addition of conditioned media from differentiatedT-HESC
cells treated with siRNAs against Nodal relative to scrambled control (n = 3).
*P < 0.05.
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FIGURE 6 | Activin-A in conditioned media from undifferentiated and differentiatedT-HESC cells. Activin-A concentration levels in conditioned media from
undifferentiated (n = 4) (A) and differentiated (n = 2) (B)T-HESC cells transfected with empty vector, wildtype (WT) or H165R Nodal constructs. *P < 0.05;
**P < 0.01.
SNP, which exhibits signiﬁcantly reduced bioactivity (Roessler
et al., 2009). Interestingly, mice with uterine-speciﬁc knockout
of Nodal in the maternal decidua have increased levels of Nodal
and Stox1 mRNA expression in the fetal placenta. In humans,
conditioned media of ﬁrst trimester decidual tissues carrying the
NODAL H165R SNP or transfected with Nodal siRNAs were also
able to upregulate NODAL and STOX1 in SGHPL-5 cells, repre-
sentative of ﬁrst trimester extravillous trophoblast cells. This study
also shows for the ﬁrst time that Nodal in human ﬁrst trimester
decidua is localized in glandular epithelial and decidual stromal
cells. As it was not known which of these two cell types was the
cause of the effects seen in trophoblast cells when conditioned
media of decidual tissues were used, cell lines representative of
both cell types were investigated in more detail. Glandular epithe-
lial cells were represented by Ishikawa cells, but these were found
not to give the effects observed as seen when using decidual tissues.
For decidual stromal cells the T-HESC cell line was used which is
able to differentiate from an endometrial stromal toward a decid-
ualized cell type, similarly as it occurs in ﬁrst trimester decidual
tissue during placental development. From the results obtained it
can be concluded that undifferentiated T-HESC cells, representing
endometrial stromal cells, cause the effects observed in decidual
tissues as described above. Furthermore, it can be concluded that
the upregulation of Nodal, and potentially STOX1, in the fetal
placenta upon knockdown of Nodal in the maternal decidua is
established, at least in part, by upregulation of Activin-A. Figure 7
shows the model proposed on how this biological interaction at
the maternal–fetal interface occurs.
Our ﬁndings nicely ﬁt into the current knowledge regarding
Nodal and Activin-A involvement in PE; in this study we pro-
vided evidence that downregulation of Nodal in decidua increases
NODAL expression in fetal trophoblast cells. In mice decidual
Nodal downregulation causes PE related symptoms of IUGR and
preterm birth (Park et al., 2012), while in human pre-eclamptic
FIGURE 7 | Model of the interaction between maternal Nodal and fetal
Nodal at the maternal–fetal interface. Reduced expression of Nodal in
endometrial stromal cells in the decidua, for instance due to NODAL-H165R
alleles carried, leads to upregulation of Activin-A. Excreted Activin-A is
subsequently able to upregulate Nodal, and potentially STOX1, in fetal
extravillous trophoblasts.
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mothers reduced bioactivity of Nodal is suggested as they carry the
NODAL-H165R SNP. Several studies have suggested and shown
that Nodal plays an important role during placental development
(Wang and Tsang, 2007). For example, it has been shown that
Nodal upregulation induces apoptosis and inhibits proliferation
of a trophoblast cell line (HTR8/SVNeo) leading to reduced inva-
sion (Munir et al., 2004). More importantly, Nodal has also been
found to be increased in placentas from pre-eclamptic patients
(Nadeem et al., 2011). In this study we furthermore observed that
reduced Nodal activity in the maternal decidua induced Activin-A
transcription leading to increased levels of Activin-A excretion.
Multiple studies have found increased Activin-A concentrations
in maternal serum of pre-eclamptic patients (Giguere et al., 2010).
Althoughwe did not provide direct evidence that the increased lev-
els of Activin-A are causing the upregulated NODAL expression
in trophoblast cells, this has recently been shown in another study
where it was observed that increasedActivin-A levels induce Nodal
expression and its subsequent signaling in trophoblast cells (Yu
et al., 2012). We are therefore conﬁdent to conclude that the Nodal
upregulation in trophoblasts is, at least in part, caused by Activin-
A upregulation in the decidua due to reduced Nodal activity in
this tissue.
To summarize, we show in this study that maternal Nodal
inversely affects fetal NODAL and STOX1 expression levels, poten-
tially through Activin-A signaling. As both Nodal and Activin-A
have been implicated in PE this interaction at the maternal–fetal
interface might play a substantial role in the development of PE.
MATERIALS AND METHODS
NODAL GENOTYPING IN PRE-ECLAMPSIA PATIENTS
Genomic DNA of the Dutch pre-eclampsia families, as described
in van Dijk et al., 2005, was sequenced to identify nucleotide
variations in exons of the NODAL gene. For sequencing, PCR
fragments were puriﬁed and subjected to cycle sequencing using
Big Dye terminators and analyzed using a Genetic Analyzer
3130xl (Applied Biosystems). Primer sequences are available upon
request.
qPCR ON UTERINE-SPECIFIC NODAL KNOCKOUT MICE TISSUES
The generation of uterine speciﬁc Nodal knockout in mice
has been previously described (Park et al., 2012). In short,
mice with loxP sites ﬂanking exons 2 and 3 of the Nodal
gene (NodalloxP/loxP) and Pgr-Cre mice (PgrCre/+) were crossed,
and double heterozygote offspring (NodalloxP/+, PgrCre/+) were
crossed with NodalloxP/+, Pgr+/+ mice to acquire the tissue-
speciﬁc, conditional knockout strain (Nodal/) and controls
(Nodal+/+). Uterine horn tissues of control (Nodal+/+) and
knockout (Nodal/) mice d16.5 (n = 6) were ﬁxed in for-
malin. Placental disks were dissected from the uterine horns,
homogenized and RNA was isolated using the FFPE RNeasy kit
(Qiagen). High Capacity RNA-to-cDNA kit (Applied Biosystems)
was used to obtain cDNA, which was pre-ampliﬁed using preAmp
mix (Applied Biosystems) followed by quantitative PCR using the
taqman universal PCR mix (Applied Biosystems) in an ABI7300.
Murine-speciﬁc taqman expression assays were used recognizing
Stox1 and Nodal (Applied Biosystems). Normalization was done
using an assay for Gapdh.
HUMAN FIRST TRIMESTER DECIDUA TISSUES
First trimester deciduas were obtained at the time of elective
surgical terminations of pregnancy (gestational age week 6–9).
Informed consent was obtained from each patient and collections
were approved by the Ethical Committee of the VU University
Medical Center and the Flevoziekenhuis Almere. Tissue was col-
lected into ice-cold PBS. After extensive washing decidua parietalis
was assessed for the integrity of the apical epithelial surface to
conﬁrm decidual origin. The tissues were cut into 3 mm3 cubes
and placed in 24 well plates (three cubes per well in 800 μl
phenol-red free DMEM/F12 supplemented with pen-strep and
Amphotericin B) and placed overnight at 37◦C, 3% O2, 5%
CO2. The second day media was refreshed. After 72 h the con-
ditioned media were collected, centrifuged to remove dead cells
and stored at −80◦C. In case of genotyping for NODAL H165R
(n = 8), DNA of decidua was extracted from the tissues and
sequenced. In case of siRNA transfection of the decidual tis-
sues (n = 4), at day 2 lipofectamine RNAiMAX (Invitrogen)
was used to transfect the tissues with NODAL siRNAs (Qiagen
ﬂexitube genesolution) or scrambled control. Also after 72 h con-
ditioned media were collected and knockdown was conﬁrmed by
quantitative RT-PCR on RNA isolated from the tissues and West-
ern Blot on protein extracted from the tissues. Knockdown was
around 50%.
IMMUNOHISTOCHEMISTRY
Human ﬁrst trimester decidual tissues from 6 to 14 weeks of
pregnancy were obtained as described above. Tissues were embed-
ded in TissueTek and stored at −80◦C. Using cryostat, frozen
tissue blocks were sectioned (10 μm) and ﬁxed in acetone for
10 min. After rinsing, blocking was performed for 1 h in
0.1% blocking reagent (Roche) in wash buffer containing PBS
with 0.05% (v/v) Tween-20. All slide incubations were carried
out in a humidiﬁed chamber at room temperature. Following
blocking, sections were incubated with Nodal antibody (1:200)
or cytokeratin-7 antibody (1:500; Santacruz) for 1 h, washed
and secondary antibodies (1:300; anti-rabbit alexa-ﬂuor-546 and
anti-mouse alexa-ﬂuor-488) were added for 1 h. After washing,
slides were dehydrated and mounted in Vectashield containing
DAPI nuclear stain (Vector Laboratories) and examined under
a microscope. For negative controls the primary antibody was
omitted.
T-HESC CELL CULTURE, DIFFERENTIATION AND
TRANSFECTION
T-HESC endometrial stromal cells were obtained from ATCC and
grown in phenol-red free DMEM/F12 media supplemented with
charcoal treated FBS, ITS+, pen-strep, and puromycin at 37◦C,5%
CO2. Differentiation was performed by the addition of 0.5 mM
8-Bromo-cAMP, 1 μM progesterone and 10 nM Estradiol (all
obtained fromSigma) on every third day. Differentiationwas com-
plete after 12 days as observed by a change in cellmorphology and a
20-fold increase in prolactin excretion as measured in conditioned
media.
T-HESC siRNA transfections in undifferentiated (ﬁve inde-
pendent experiments) and differentiated (three independent
experiments) cells were done as described for tissue transfections.
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After 72h conditionedmediawere collected, centrifuged to remove
dead cells and stored at −80◦C. Knockdown was assessed by
quantitative RT-PCR and Western blotting. Knockdown of Nodal
mRNA and protein was at least 75%.
A vector to express Nodal protein was constructed in a
pF5K-cmv-neo ﬂexi vector (Promega) according to the ﬂexi-
vector protocol. The H165R SNP was introduced by using
the Quickchange XL site-directed mutagenesis kit (Stratagene).
Integrity of the constructs was veriﬁed by sequencing. Trans-
fection in undifferentiated (four independent experiments) and
differentiated (two independent experiments) of the constructs
and empty vector was done using Fugene HD transfection reagent
(Roche). After 72 h conditioned media were collected, cen-
trifuged to remove dead cells, and stored at –80◦C. Overexpression
of Nodal was conﬁrmed by quantitative RT-PCR and Western
blotting.
SGHPL-5 CELL CULTURE AND QUANTITATIVE RT-PCR
Different concentrations of conditioned media obtained from
(transfected) decidual tissues and T-HESC cells were added in
duplicate to 4,00,000 SGHPL-5 cells, kindly provided by Dr Judith
Cartwright, St George’s University of London, UK, per well in
12 well plates. After 30 h SGHPL-5 cells were collected and RNA
isolated using the RNeasy kit (Qiagen). Quantitative RT-PCRs
were performed in triplicate on an ABI7300 using the Taqman
EZ RT-PCR kit (Applied Biosystems) with a gene expression assay
for NODAL (Applied Biosystems) and primers and probe rec-
ognizing STOX1 isoform A as described before (van Dijk et al.,
2010a). Normalization was done with gene expression assays for
GAPDH.
TFG-β/BMP SIGNALING PATHWAY PCR ARRAY AND ACTIVIN-A ELISA
RNA from siRNA transfected undifferentiated T-HESC cells and
decidua tissue as described above was used on a TGF-β/BMP
signaling pathway PCR array (SABbiosciences) according to the
manufacturer’s instructions.
To conﬁrm the results obtained by this array, Activin-A pro-
tein secretion was analyzed in duplicate in the conditioned media
of transfected decidua tissues and T-HESC cells, obtained as
described above, using an ELISA for Activin A (Activin-A Human
ELISA kit, Abcam) according to the manufacturer’s protocol and
analyzed on a Biotek synergy HT micro plate reader at 450 nm
using Gen5 software.
STATISTICS
All data are calculated and expressed as mean ± SEM. Results were
subjected to statistical analysis by Student’s t-tests as appropriate
using Prism 5.0c (GraphPad Prism, San Diego, CA, USA) and sig-
niﬁcance was accepted when P < 0.05. All graphs are based on
the combined data of independent samples or transfections used,
except the graph of 6A that shows a representative graph of one of
the four independent transfections performed.
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